Please assess the completion status of the following clinical trial:

Trial Title: MDMA-Assisted Psychotherapy in People With Posttraumatic Stress Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have current PTSD (within the past 6 months) in response to crime victimization, including childhood sexual or physical abuse, or meet criteria for PTSD in response to combat;~* Have a CAPS score showing moderate to severe PTSD symptoms;~* They must either:~  1. Have had at least one unsuccessful attempt at treatment for PTSD with a SSRI and psychotherapy;~ 2. Be a veteran with PTSD symptoms that have endured for no less than one year but no more than five years~* Be at least 18 years old;~* Must be generally healthy;~* Willing to remain overnight at the study site;~* Agree to have transportation home the morning after experimental sessions;~* Are willing to be contacted via telephone for all necessary telephone contacts;~* Must have a negative pregnancy test if able to bear children and agree to use an effective form of birth control;~* Are proficient in reading English;~Exclusion Criteria:~* Are pregnant or nursing, or are able to bear children and are not practicing an effective means of birth control;~* Weigh less than 50 kg or more than 105 kg;~* Are unable to give adequate informed consent;~* Prior use of Ecstasy (illicit drug preparations purported to contain MDMA) more than 5 times or at any time within the previous 6 months;~* Have a history of certain excluded medical disorders.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- MDMA-assisted therapy (125 mg) (Type: EXPERIMENTAL): Participants will receive an initial dose of 125 mg midomafetamine HCl orally followed 2 to 2.5 hours later by a second dose of 62.5 mg midomafetamine HCl during two 8-hour long blinded therapy sessions.
- Placebo with therapy (Type: PLACEBO_COMPARATOR): Participants will receive an initial dose of 125 mg placebo orally followed 2 to 2.5 hours later by a second dose of 62.5 mg placebo during two 8-hour long blinded therapy sessions.

Based on this trial design, predict the completion outcome and termination type (if applicable).